Bristol Myers's most recent trend suggests a bearish bias. One trading opportunity on Bristol Myers is a Bear Call Spread using a strike $61.50 short call and a strike $66.50 long call offers a potential 34.77% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $61.50 by expiration. The full premium credit of $1.29 would be kept by the premium seller. The risk of $3.71 would be incurred if the stock rose above the $66.50 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Bristol Myers is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.
The RSI indicator is at 30.38 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
Bristol-Myers Squibb (BMY) Stock Moves -1.59%: What You Should Know
Thu, 05 Mar 2020 22:45:10 +0000
Bristol-Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.59% move from the prior day.
Biopharma Could Outperform Volatile Market, Analyst Says
Thu, 05 Mar 2020 17:27:00 +0000
Take a look at biopharma, Bank of America analyst Geoff Meacham argues in a new note out Thursday. “Despite market volatility from [coronavirus], we expect limited impact on biopharma fundamentals,” Meacham wrote. Meacham played down the excitement over possible treatments and vaccines for Covid-19, saying that they remain months, or even a year, away.
Bristol-Myers Named a Bank of America Top Pick Amid Coronavirus Fallout
Thu, 05 Mar 2020 13:30:00 +0000
Bristol-Myers Squibb is tapped a Bank of America top pick amid coronavirus fallout. The New York pharma giant has a buy rating and $75 price target.
The No. 1 Pharma Stock Just Topped A Buy Point — Is BMY Stock A Buy?
Thu, 05 Mar 2020 13:00:05 +0000
Pharmaceutical company Bristol-Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
These 4 Pharma Stocks Are Outplaying 90% Of The Stock Market
Wed, 04 Mar 2020 16:00:07 +0000
Pharmaceutical stocks dipped a by single-digit percentage in the first two months of 2020, trailing their biotech brethren. Still, there are standout companies among the industry group.
Related Posts
Also on Market Tamer…
Follow Us on Facebook